Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009
Elpiscience Biopharmaceuticals, a China-based biopharmaceutical company, has announced that the first patient has been dosed...
Drug
Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH
Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...
ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...
Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...
LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China
Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...
Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast
Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...
Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment
Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...
United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment
United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...
BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02
BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...
Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China
The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
EC Approves AbbVie’s Tepkinly for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its bispecific...
Sanofi’s Altuviiio Receives Marketing Approval from Japan’s MHLW for Hemophilia A Treatment
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...
Japan’s MHLW Approves Eisai and BioArctic’s Leqembi for Alzheimer’s Treatment
The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted approval to Eisai...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Two Cancer Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Novartis’ Lutathera Meets Primary Endpoint in Phase III Trial for GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that a Phase III trial for its...
AffaMed Therapeutics’ Luminate Receives Clinical Trial Approval for Dry AMD in China
AffaMed Therapeutics, a China-based biotech firm, has announced the receipt of its first clinical trial...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20105 Clinical Study in Solid Tumors
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a China-based pharmaceutical company, has announced that it...
Shanghai Junshi’s Tuoyi Meets Primary Efficacy Endpoint in Phase III Melanoma Study
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Abbisko Therapeutics Gets NMPA Approval for Irpagratinib Combination Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has received approval from the National...
Hepagene Therapeutics’ HPG7233 Receives US FDA IND Approval for NASH Treatment
Hong Kong-based biopharmaceutical company Hepagene Therapeutics Inc. has announced that the US Food and Drug...